Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01134692
Other study ID # NG002
Secondary ID
Status Recruiting
Phase Phase 3
First received June 1, 2010
Last updated June 1, 2010

Study information

Verified date May 2010
Source Govind Ballabh Pant Hospital
Contact Nitin Gupta, MD
Phone +919718599209
Email drnitingupta_id@rediffmail.com
Is FDA regulated No
Health authority India: Ministry of Health
Study type Interventional

Clinical Trial Summary

Chronic peripheral and splanchnic vasodilatation are the hallmark hemodynamic abnormality in cirrhosis and contribute to the pathogenesis of portal hypertension.

Alterations in intestinal motility and bacterial overgrowth in gut may predispose to the development of bacteraemia and endotoxaemia in cirrhotic patients which play a role in the hyperdynamic circulatory syndrome of cirrhosis. Probiotic therapy is aimed at changing the make-up of the indigenous microflora by administering specific strains of non-pathogenic and potentially beneficial microflora. In this study, the investigators hypothesize that a modification in the composition of the endogenous digestive microflora by oral bacteriotherapy with high potency probiotic preparations could be a safe way to regulate the portal pressure.

As there is a relative paucity in effective pharmacological treatment for portal hypertension, these novel and innovative therapy might provide important alternative or adjunct therapy to beta blockers in the clinical management of patients with portal hypertension.

Aims and objectives

To study in patients with cirrhosis and large varices whether probiotics and/or norfloxacin given for 2 months :

1. achieve a reduction in HVPG

2. alter the endotoxin and cytokine levels, and improve systemic inflammatory responses

3. well tolerated.

Inclusion criteria:

Consecutive patients of cirrhosis with portal hypertension who fulfill the following criteria:

1. Diagnosed cases of cirrhosis (by clinical, biochemical and radiological criteria with or without liver biopsy)

2. No history of upper GI bleeding in the past

3. Endoscopically documented large esophageal varices

Exclusion criteria

1. history of gastrointestinal bleeding

2. patients who have received beta blockers for portal hypertension in the past 6 weeks.

3. hepatic encephalopathy

4. ongoing bacterial infection,

5. Spontaneous bacterial peritonitis

6. active alcoholism or illicit drug abuse

7. alcoholic hepatitis

8. Treatment with antibiotics in the preceding 2 weeks.

9. presence of hepatocellular carcinoma,

10. portal vein thrombosis

11. serum creatinine>1.5 mg/dL,

12. treatment with vasoactive drugs in the past 6 weeks,

13. history of arterial hypertension, congestive heart failure or arterial occlusive disease, and

14. Refusal to participate.

15. Active smokers.

Study plan:

Ethical approval will be obtained prior to study initiation. Patients presenting to Department of Gastroenterology, GB Pant Hospital will be recruited in the study. Patients will be evaluated regarding the eligibility for the study. After being found eligible for the study, if the patient agrees to participate in the study, a signed informed consent will be obtained. Baseline HVPG will be measured in all patients and then they will be randomized into 3 groups:.

1. Group 1: Beta blockers + placebo

2. Group 2: Beta blockers + Norfloxacin (400mg BD)

3. Group 3: Beta blockers + probiotics. (one sachet of VSL#3 BD)

30 patients will be enrolled into each group. The treatment will be continued for 2 months.

The study design is a randomized double-blinded placebo controlled trial.

Once patients have been enrolled, they will undergo baseline investigations. Blood will be drawn from both peripheral and hepatic veins and sent for routine parameters, pro-inflammatory cytokines (IL-1b, IL-6, IL-10, TNF-α, endotoxins, NO2 and NO3 levels, PRA, BNP). Samples will be stored at -70 ºC. Baseline vitals will be recorded.

Patients will be called at the end of 1 month for assessment of compliance and then at the end of the study (2 months) to repeat the HVPG and the same parameters as at the time of enrollment

End Points:

1. Primary

a. Change in HVPG levels as compared with baseline, to define responder (≥20% reduction in HVPG or ≤ 12 mm Hg).

2. Secondary

1. Change in digestive flora

2. Reduction in serum and hepatic endotoxin and cytokine levels

3. Assessment of improvement in the renal parameters and Systemic inflammatory response syndrome

4. Improvement in the markers of oxidative injury

5. Adverse effects


Recruitment information / eligibility

Status Recruiting
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 12 Years to 75 Years
Eligibility Inclusion Criteria:

Consecutive patients of cirrhosis with portal hypertension who fulfill the following criteria:

1. Diagnosed cases of cirrhosis (by clinical, biochemical and radiological criteria with or without liver biopsy)

2. No history of upper GI bleeding in the past

3. Endoscopically documented large esophageal varices

Exclusion Criteria:

1. history of gastrointestinal bleeding

2. patients who have received beta blockers for portal hypertension in the past 6 weeks.

3. hepatic encephalopathy

4. ongoing bacterial infection,

5. Spontaneous bacterial peritonitis

6. active alcoholism or illicit drug abuse

7. alcoholic hepatitis

8. Treatment with antibiotics in the preceding 2 weeks.

9. presence of hepatocellular carcinoma,

10. portal vein thrombosis

11. serum creatinine>1.5 mg/dL,

12. treatment with vasoactive drugs in the past 6 weeks,

13. history of arterial hypertension, congestive heart failure or arterial occlusive disease, and

14. Refusal to participate.

15. Active smokers.

Study Design

Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Propranolol, Norfloxacin, VSL#3
Propranolol: as per heart rate titration Norfloxacin: 400mg BD

Locations

Country Name City State
India GB Pant hospital Delhi

Sponsors (1)

Lead Sponsor Collaborator
Govind Ballabh Pant Hospital

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in HVPG levels as compared with baseline, to define responder (=20% reduction in HVPG or = 12 mm Hg). 2 months No
Secondary Assessment of improvement in the renal parameters and Systemic inflammatory response syndrome 2 months No
Secondary Adverse effects 2 months Yes
See also
  Status Clinical Trial Phase
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05014594 - Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT Phase 2
Not yet recruiting NCT03631147 - The Effect of Rifaximin on Portal Vein Thrombosis N/A
Completed NCT04939350 - Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
Completed NCT02528760 - To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis N/A
Recruiting NCT05484206 - Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Phase 1
Not yet recruiting NCT05538546 - Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients
Not yet recruiting NCT04053231 - Hepatocarcinoma Recurrence on the Liver Study - Part2
Recruiting NCT02983968 - Use of the French Healthcare Insurance Database
Completed NCT02705534 - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Phase 3
Completed NCT02596880 - Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics Phase 3
Completed NCT02247414 - Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Phase 4
Withdrawn NCT01956864 - Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer Phase 1
Completed NCT02016196 - Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS Phase 3
Completed NCT02113631 - Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir N/A
Completed NCT01362855 - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Completed NCT01447537 - Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis N/A
Active, not recruiting NCT01205074 - ¹³C-Methacetin Breath Test (MBT) Methodology Study Phase 2/Phase 3
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01231828 - Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies. N/A